Tandem Diabetes Care Inc (TNDM)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -96,025 | -222,611 | -94,594 | 15,566 | -34,382 |
| Total stockholders’ equity | US$ in thousands | 263,098 | 313,632 | 439,947 | 433,112 | 366,305 |
| ROE | -36.50% | -70.98% | -21.50% | 3.59% | -9.39% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-96,025K ÷ $263,098K
= -36.50%
The return on equity (ROE) for Tandem Diabetes Care Inc has displayed fluctuations over the years as per the provided data.
- As of December 31, 2020, the ROE was -9.39%, indicating that the company generated a negative return on the shareholders' equity.
- By December 31, 2021, the ROE improved to 3.59%, showing a positive but relatively low return on equity.
- The ROE significantly declined to -21.50% by December 31, 2022, reflecting a substantial reduction in the company's profitability as compared to the previous year.
- The ROE plummeted to -70.98% by December 31, 2023, indicating a severe decline in the company's ability to generate profits relative to its equity.
- As of December 31, 2024, the ROE improved slightly to -36.50%, but it still remained in the negative territory, signifying ongoing challenges in creating value for shareholders.
Overall, Tandem Diabetes Care Inc's ROE has been volatile and mostly negative during the period under review, suggesting difficulties in efficiently utilizing shareholder equity to generate profits. This trend might raise concerns for investors and stakeholders regarding the company's long-term financial performance and operational efficiency.
Peer comparison
Dec 31, 2024